Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Halozyme Therapeutics , a biopharmaceutical company that develops human enzymes for therapeutic use, rose as much as 13% after announcing the appointment of Helen Torley as president and CEO of Halozyme after the closing bell last night.

So what: According to the press release from Halozyme, Torley will be joining Halozyme as the president and CEO as of Jan. 6, replacing Gregory Frost who is leaving to assume the head of the health sector operations for Intrexon on the same day. Dr. Frost, however, will remain on Halozyme's scientific advisory board. Dr. Torley brings with her 14 years of management experience and most recently worked at Onyx Pharmaceuticals, which was recently acquired by Amgen.


Now what: There are two factors at work pushing shares higher today. First, shareholders love clarity, and with no need for a long-winded search for a new CEO investors seem quite pleased with the announced executive transition. The other factor at play here is that Torley handled the oversight of Onyx's successful pipeline and investors have to be thinking that she may be able to do the same for Halozyme. Although Halozyme is still relatively green when it comes to its product portfolio, there's certainly plenty of collaborative potential here that bears watching by investors.

Here's another strong growth opportunity you should be watching
Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.

The article Why Halozyme Therapeutics Inc. Shares Jumped originally appeared on Fool.com.

Fool contributor  Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle  @TMFUltraLong . Try any of our Foolish newsletter services free for 30 days . We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights  makes us better investors. The Motley Fool has a disclosure policy .

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Investing in Real Estate

Learn the basics of investing in real estate.

View Course »

Reading a Stock Quote

Learn to read the ingredients of a stock.

View Course »

Add a Comment

*0 / 3000 Character Maximum